
Matinas BioPharma fell 3.0% from $0.83 to $0.80, behind the S&P 500's +4.7%. Its worst day was Jul 13 (−36.4%), and its low came Sep 15 at $0.16.
Nov 21, 2025 – Nov 20, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-3.90 was reported on $0.00 revenue.
+10.0% · S&P 500 +0.8%
EPS of $-4.50 was reported on $0.00 revenue.
Story events cover the past 12 months · Times ET
+0.3% · S&P 500 +0.2%
EPS of $-3.15 was reported on $0.00 revenue.
+0.4% · S&P 500 −0.2%
Matinas BioPharma closed at its lowest level of the year, 80.6% below where the year started.
−16.7% · S&P 500 −0.5%
Matinas BioPharma shares rose 1248.3%, while the S&P 500 rose 0.5%.
+1248.3%, the year's best day · S&P 500 +0.5%
Matinas BioPharma closed at its highest level of the year, 264.8% above where the year started.
+6.7% · S&P 500 +0.5%
EPS of $-9.35 was reported on $0.00 revenue.
−7.7% · S&P 500 −1.0%
Where it ended: a close of $0.80 on Nov 20, 2026.
Nothing in the past 12 months.
All MTNB analyst actionsNothing in the past 12 months.
All MTNB dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for MTNB and SPY from Benzinga historical bars. Not investment advice.